MCL Featured Stories

Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins the “Fierce Healthcare” podcast to discuss how organizations can cultivate resiliency and agility amidst a changing healthcare landscape.

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

PACE / State of FL - In this webinar we'll address the critical role of planning to support innovation and transformation in today's laboratory outreach environment, particularly related to Information Technology initiatives. The pandemic has accelerated the need for efficient workflows and digital solutions, and the laboratory outreach program needs to keep up. We'll delve into practical tools and insightful strategies to help you navigate the challenges related to implementing these initiatives in your laboratory.

The most successful laboratory outreach programs recognize the importance of serving multiple customers. From provider to patient to healthcare consumer, the laboratory has an opportunity to serve them all with high-quality results and excellent service. When aligning testing with community awareness and patient needs, the laboratory outreach program can strategically plan for future success.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Chancey Christenson, M.D., about the lab's important role in healthcare.

Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

PACE/FL -
This webinar will provide a brief history of the FDA’s interest in LDTs and review the new requirements in detail, serving as an introduction to medical device regulations in the context of a clinical laboratory.

Mayo Clinic Laboratories introduces an advancement in the management of Crohn's disease with the release of a new laboratory test that measures Risankizumab levels in patients. This test will advance the therapeutic monitoring of Crohn's disease, enabling personalized treatment approaches.

As we prepare to celebrate this year's Lab Week, the Mayo Collaborative Services Education team not only wants to highlight your important work as medical laboratory professionals and pathologists, but also help you feel more confident in your role by sharing the following educational resources that may give you additional knowledge and opportunities to advance in your career. 

Medical Laboratory Professionals Week, also known as Lab Week, provides us with the opportunity to increase our understanding of and appreciation for clinical laboratory personnel. We celebrate their efforts to provide critical answers for patients every day and drive innovation in the field of medicine.

Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff

Mayo Clinic Laboratories introduces the Inherited Parkinson’s Disease Gene Panel (Mayo ID: PARDP), a collaborative breakthrough poised to transform Parkinson’s disease diagnosis and treatment. Led by Rodolfo Savica, M.D., Ph.D., and Zhiyv (Neal) Niu, Ph.D., this comprehensive test offers unparalleled insights into Parkinson’s genetics, unveiling novel gene associations and enhancing diagnostic precision through next-generation sequencing. The panel’s capabilities include detecting subtle genetic variations and identifying familial patterns, promising personalized medicine advancements.